Who are Jasper Therapeutics, Inc.'s main suppliers?

Jasper Therapeutics, Inc. (JSPR) key suppliers include: STANFORD, CIRM, Septerna, Inc.. View the full supplier network at chainsifter.com/chain/JSPR.

Who are Jasper Therapeutics, Inc.'s major customers?

Jasper Therapeutics, Inc. (JSPR) key customers include: LONZA-SALES-AG, USA-LLC. View the full customer network at chainsifter.com/chain/JSPR.

What sector is Jasper Therapeutics, Inc. in?

Jasper Therapeutics, Inc. (JSPR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Jasper Therapeutics, Inc. Supplier List (JSPR): 3 Verified Suppliers

3Suppliers

2Customers

2Debt Items

11Related Chains

Source-Backed Evidence Depth

Jasper Therapeutics, Inc. (JSPR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

8Total relationships

1Distinct source URLs

6High confidence

0.824Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Jasper Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
STANFORD	STANFORD	90%	Stanford transferred to the Company certain know-how and patents related to briquilimab
CIRM	CIRM	80%	The Company has received an aggregate of $ 2.3 million from CIRM through March 31, 2026
SEPN	Septerna, Inc.	72%	Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated prob…

Jasper Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
LONZA-SALES-AG	LONZA-SALES-AG	85%	ractices (“cGMP”) regulations for use in our clinical trials. The manufacture of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requiremen…
USA-LLC	USA-LLC	62%	l research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors, including the safety and e…

Jasper Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
JSPR-DEBT-10464	Warrants outstanding: 0.0001	90%	xbrl warrant detail from xbrl 2025-12-31.
JSPR-DEBT	Debt stack $757,000	90%	Market cache reports total debt of $757,000.

Jasper Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Jasper Therapeutics, Inc..

Jasper Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
JSPR-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 65 tracked holders.

Jasper Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CLDX	Celldex Therapeutics, Inc.	100.00	2
BBIO	BridgeBio Pharma, Inc.	100.00	2
VKTX	Viking Therapeutics, Inc.	100.00	2
TERN	Terns Pharmaceuticals, Inc.	100.00	2
LLY	Eli Lilly and Company	100.00	2
MBX	MBX Biosciences, Inc.	100.00	2
GPCR	Structure Therapeutics Inc.	100.00	2
ORANY	ORANGE	50.00	2
BAC	Bank of America Corporation	50.00	2
SEPN	Septerna, Inc.	36.29	1	['supplier']
VERTEX	VERTEX	24.13	2

Jasper Therapeutics, Inc. Supply Chain